483
Molecular PharmaGroupFDA 483 - Molecular PharmaGroup - December 11, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Molecular PharmaGroup, an outsourcing facility in New Providence, NJ, revealed two significant observations. The firm failed to include required information on its drug product labels, such as the facility's address and a list of ingredients. Additionally, Molecular PharmaGroup did not submit a report to the FDA identifying products compounded during a previous six-month period.
Open in Dashboard
ID · 302fe2d2-ed08-4c5a-b31d-245b2174b3ef